Printer Friendly

Memorial Sloan Kettering confirms immunomodulatory effects on Maitake extract.

At the Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago (May 30-June 3, 2008), Memorial Sloan Kettering Cancer Center (MSKCC) announced the results of a government-funded clinical study, begun in 2004, which confirms the immunomodulatory effects of Maitake extracts as well as "no dose-limiting toxicity." The MSKCC study also concluded that the clinical significance is as yet unknown. The study was conducted on a crude extract from maitake mushroom (Crifola frondosa). In 2004, researchers at MSKCC, together with Cornell University Medical College, published the result of another laboratory study that showed a significant enhancement of bone marrow colony formation with the use of crude Maitake extracts as well as a reduction in the toxicity induced by an anticancer drug. (1)

Mike Shirota, CEO of Maitake Products, Inc., welcomes the study: "Our Grifron[R]--Pro Maitake D-Fraction[R] has already been under a clinical trial with advanced breast and prostate cancer patients under Investigational New Drug (IND) approval by the FDA. The new clinical study at MSKCC, one of the nation's most prominent cancer institutes, will significantly strengthen scientific validation of Maitake extracts, although it was not carried out on a purified and standardized extract like our Grifron[R] Pro Maitake D-Fraction[R]." Maitake Products, Inc. is an official Corporate Cancer Research Sponsor of the Memorial Sloan Kettering Cancer Center.

Maitake Products Inc.'s Maitake D-Fraction[R] line of Maitake extract products are the only ones available commercially that have been made for over a decade with an established active proteoglucan (D-fraction) standardization. (2) Maitake D-Fraction[R], PD Fraction[R], TD-Fraction[R], TMD Fraction[R], Grifron[R], Mushroom Wisdom[R], ProstMate[R], Mushroom Emperors[TM], and MD Fraction[TM] are registered trademarks or trademarks of Maitake Products, Inc.

(1.)Hong Lin, et al. Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Internationa! Immunopharmacology. 2004;4: 91-99 .(This study was not conducted on a finished product available in the market, such as Maitake Products Inc.'s MD Fraction[TM])

(2.)Ikuko Hishida, et al. Antitumor activity exhibited by orally administered extract from fruit body of Crifohi frondosa (maitake). Chem. Pharm. Bull. 1988;36(5):1819-1827. (This study was not conducted on a finished product available in the market, such as Maitake Products Inc.'s Maitake D-Fraction[R]).
COPYRIGHT 2008 The Townsend Letter Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Townsend Letter
Date:Aug 1, 2008
Previous Article:Introducing Laboratory Evaluations for Integrative and Functional Medicine.
Next Article:AACR introduces Cancer Prevention Research, a new journal devoted exclusively to the growing science of cancer prevention.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters